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Aims.Theaimofthis studywas toevaluate thepotential ofvisualizing chronic myocardial infarction inpatients usingthe intravas-
cular CA MS-325 (gadofosveset, EPIX Pharmaceuticals, Mass, USA). Methods. Nine patients were enrolled in a clinical phase II
multicenter trial for MRCA and perfusion imaging using MS-325. They had objective evidence of chronic myocardial infarction as
visualizedbypreviouslyperformedlategadolinium(Gd)enhancementimaging(LGE)withaconventionalextracellularGd-DTPA
CA (Magnevist, Bayer Healthcare, Germany, 0.2mmol/kg/body weight) serving as reference standard. A prepulse-optimized LGE
study was performed immediately and at several time points after injection of MS-325 (0.05mmol/kg/body weight). The number
and localization of segments demonstrating LGE with MS-325 as well as signal intensities were compared with the reference stan-
dard(Gd-DTPA).Results.UsingMS-325,LGEcouldbedetectedateverytimepointinall9patients.TheaccuracyofLGEwithMS-
325 as compared to LGE with Gd-DTPA was highest 54 ± 4 minutes after contrast injection, resulting in a sensitivity of 84% with
a speciﬁcity of 98%. Conclusion. The intravascular CA MS-325 has the potential to visualize chronic myocardial infarction. How-
ever, in comparison with Gd-DTPA, the transmural extent and the number of segments are smaller.
1.Introduction
Intravascular blood pool contrast agents (CAs) have been
designed and studied in order to improve MR coronary
artery imaging (MRCA) and peripheral MR angiography [1–
8]. A possible approach is the use of gadolinium-based albu-
min-bound CA that has longer residence time in the blood
pool, while the free, unbound components behave in a simi-
lar manner to extracellular media. The potential of such new
aspects for the detection of myocardial scar has been studied
in various animal models [9–11] with promising results. So
far, no data for scar detection using intravascular CA in
humans have been described.
Infarct size and its transmural extent are important pre-
dictors for the likelihood of functional recovery and patient
prognosis[12–14].Magneticresonancelategadoliniumenh-
ancement (LGE) using a gadolinium-based (Gd) extravascu-
lar contrast agent is a reliable technique for the detection of
myocardial scar and can be used to distinguish between
reversible and irreversible myocardial damage [15–17]. The
technique can be regarded as reference standard in clinical
routine, and its reproducibility has been demonstrated [18].
We evaluated the potential of the intravascular CA MS-
325 for detection of myocardial scar in patients with chronic
myocardial infarction.
2.MaterialsandMethods
2.1. Study Protocol. The results presented here were obtained
as a single-center protocol within a multicenter phase II
trial for feasibility and sequence optimization of MS-3252 The Scientiﬁc World Journal
(gadofosveset;Vasovist)forcombinedMRmyocardialperfu-
sion imaging and MRCA. The study protocol was approved
by the Charit´ e and Virchow-Klinikum Institutional Ethics
Committee, and all subjects gave informed consent prior to
the cardiovascular magnetic resonance (CMR) examination.
Patients were then scheduled for MRCA and perfusion imag-
ing using MS-325. LGE measurements were performed in
addition to the multicenter protocol.
2.2. Patient Population. A total of nine patients (8 males,
meanage56years,range35–66years)wereincluded.Patients
were enrolled if they had evidence for chronic myocardial
infarction as determined by a previous clinically indicated
CMR examination including late gadolinium enhancement
imaging using the extracellular CA (Gd-DTPA, Magnevist,
BayerHealthcare,Germany,0.2mmol/kg/bodyweight)at1.5
Tesla MR (Philips, Intera, Best, The Netherlands). The mean
infarct age was 36 months (3–134 months), and the X-ray
coronary angiography performed within 3 months before or
one month after MR exam showed reperfusion of the sup-
plying coronary artery of the infarct area in 6 patients, chro-
nic occlusion in 2, and partial reperfusion and occlusion in
1 patient. Patients were not included if they had a history of
coronary artery bypass graft operation or presented with a
severe reduction of left ventricular function (LV-EF < 30%)
or severe valvular heart disease, were clinically unstable (e.g.,
unstable angina pectoris), had any medical history of ana-
phylactoid reaction, or had any contraindication for MRI
examination.
2.3. MS-325. MS-325 is an intravascular contrast agent that
has been designed and veriﬁed for MR angiography of the
cardiovascular system [1–5] and has been approved for MR
angiography of abdominal and peripheral vessels. It is char-
acterized by a low molecular weight of 975.88kD and low
viscosity of 3.0cP. It is constituted of a diphenylcyclohexyl
group attached to a gadolinium (Gd) chelate by a phospho-
diester linkage. Its reversible binding to human serum albu-
min (85–95%) has two major eﬀects: ﬁrst, vascular reten-
tion and low volume of distribution leading to a half-life
of 16 hours; second, the binding to albumin reduces the
molecular tumbling rate and induces better electron-nuclear
interaction between the Gd and water protons resulting in
a high relaxivity of 30–50mmol−1sec−1 (at 37◦C; depending
on B0). Thus, compared to Gd-DTPA, 5 to 10 times high-
er relaxivities can be observed depending on magnetic ﬁelds
and concentrations [1–5]. The unbound MS-325 behaves
similarly to extracellular CA with diﬀusion into the
extracellular compartment. Despite the missing interaction
with albumin, unbound MS-325 has a relaxivity of 6.5
mmol−1 sec−1 [19] compared to other extracellular CA (e.g.,
Gd-DTPA 3.5mmol−1 sec−1).
2.4. MR Imaging Protocol. All examinations were performed
witha1.5TeslaMRScanner(Intera,PhilipsMedicalSystems,
Best, The Netherlands) using a dedicated phased-array car-
diac coil (Sense-cardiac coil, Philips, Best, The Netherlands).
Patients were placed in a relaxed supine position and after a
rapid survey to determine the exact heart axis, cine loops in
3 short-axis (SA) planes (apical, equatorial, and basal), and
3 long-axis (LA) planes (4-, 3-, and 2-chamber view) were
acquired for further planning.
ReferenceLGEimaging,whereLGEusinganextracellular
CA (Gd-DTPA; Magnevist, Bayer Healthcare, Germany,
0.2mmol/kg/bodyweight) was deﬁned as the reference, was
performed using a prepared turbo gradient echo imaging
sequence (3D, TR shortest; TE shortest; ﬂip angle 15◦)wi t ha
spatial resolution of 1.4 × 1.1 × 5mm in end-expiratory
breath-hold position. Prior to each LGE measurement, a
look-locker measurement [20] was performed. Minimum
time between scanning a patient with Gd-DTPA and MS-325
was 24 hours.
The weight adapted bolus of MS-325 of 0.05mmol/
kg/body weight was administered through a power injector
(MedRad Inc., Indianola, US) with a ﬂow rate of 1.5mL/s
immediately followed by a saline ﬂush of 30mL (1.5mL/s).
LGE measurements with MS-325 were performed in SA and
LA using an inversion-prepared turbo gradient echo imaging
sequence (3D, TR 4ms; TE 1.95ms; ﬂip angle 15◦)w i t ha
spatial resolution of 1.29 × 1.29 × 5mm in end-expiratory
breath-hold position. Prior to each LGE measurement with
MS-325, a look-locker measurement [20]w a sp e r f o r m e dt o
determine the individually adapted inversion prepulse delay
for optimal suppression of myocardial signal. LGE imaging
was performed at 3 time points (t1, t2, t3). t1 was 4 ± 1
minutes after CA injection. t2 was performed after contrast-
enhanced MRCA. Since the duration of MRCA depends on
heartrateandtheeﬃciency of breathing motion suppression
(navigator eﬃciency) t2 varied between 17 and 37 minutes
with an average of 26 ± 7 minutes after CA injection, t3 was
set to 54 ± 4 minutes after injection.
2.5. MR Image Analysis. A l lM Ri m a g e sw e r ea n a l y z e do n
a dedicated workstation (ViewForum, Release 4.1; Philips,
BestTheNetherlands)andevaluatedbytwoexperiencedMR
readers.Thepresenceofmyocardialscarwasvisuallyassessed
in a 16-segment model in 3 short axis slices (6 segments:
basal, 6 segments: medial, and 4 segments: apical). Trans-
murality of infarcted segments was assessed in the short-axis
slices using a 4-point scale (1: 1–25% transmural enhance-
ment; 2: 26–50%; 3: 51–75%; 4: 76–100%).
At every time point, signal intensities were determined
for regions of interest placed inside the enhanced area, in the
left ventricular cavity (corresponding to blood pool), and in
healthy myocardium. The following values were determined:
mean, minimum, maximum, and standard deviation of the
signal intensity.
2.6. Statistical Methods. Transmurality of the enhanced seg-
ments with MS-325 was normalized to the degree of trans-
murality previously detected with the extracellular CA and
compared using a Wilcoxon signed-rank test. The number
of detected enhanced segments for both methods is given in
absolute values and percentage of the total number of asses-
sable segments. Signal intensities were compared using the
mean values, and the contrast between enhanced area, myo-
cardium, and blood pool was calculated as follows: C1,2 =
(SI1− SI2)/(0.5 × (SI1 +S I 2)[ 21]. Mean values, standardThe Scientiﬁc World Journal 3
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Figure 1: Transmural LGE detected with the extracellular CAs in long-axis and short-axis view (a and b) compared with MS-325LGE
(c and d). Both CA show a clear contrast between the enhanced area and the surrounding normal myocardium. However, blood pool signal
is brighter for MS-325 related to higher relaxivity and vascular retention.
Table 1: Averaged signal intensities (SIs) in the enhanced area,
blood pool, and normal myocardium at each time point. Values are
expressed as mean ± standard deviation.
Time point
SI t1 t2 t3
Enhanced area 911 ± 136 1073 ± 112 1254 ± 139
Blood pool 1767 ± 86 1818 ± 73 1787 ± 46
Normal myocardium 122 ± 19 113 ± 9 124 ± 12
deviations,andP valueswerecalculatedforeachdataset.The
results were assumed to be statistically signiﬁcant with a P
value <0.05.
3. Results
3.1. Number of Enhanced Segments. A l ls e g m e n t s( 9 × 16 =
144) could be evaluated with Gd-DTPA and MS-325 after
injection (Figure 1). With the extracellular CA 55, segments
were classiﬁed as having LGE. Using MS-325, LGE could be
detected at every time point in all 9 patients.
At t1, 45 segments (per segment sensitivity 82%) showed
LGE in identical segments as Gd-DTPA, 10 segments were
false negative, and 1 segment was false positive with MS-325
(per segment speciﬁcity 99%). At t2,4 1s e g m e n t sw e r et r u e
positive (per segment sensitivity 75%) with no false positive
and14falsenegative(persegmentspeciﬁcity100%).Att3,46
segments were true positive (per segment sensitivity 84%),
9 false negative and 1 false positive (per segment speciﬁcity
98%).
3.2. Transmurality. The reference LGE imaging showed a
mean transmurality of 3.2 ± 0.8. Thirteen segments (9%)
showed 25–50% transmural enhancement, 14 segments
(9%) 50–75%, and 32 segments (21%) 75–100%. None of
the segments was classiﬁed as having LGE of 1–25% trans-
murality. Using MS-325, the transmurality was signiﬁcantly
underestimated at all time points with a mean transmural
extent of 2.0 ± 0.75 (P<0.0005, 62% of LGE with extra-
cellular CA) at t1,2 . 6± 0.79 at t2 (P<0.0005, 78%), and
3 ± 0.93 at t3 (mean 3.0, 92%P<0.0005). Interestingly,
using MS-325, a tendency towards overestimation was found
at t2 and t3 for segments with 25–50% transmural extent
i d e n t i ﬁ e db yG d - D T P A ,a sw e l la sa tt3 for segments with 50–
75% transmural extent (Figure 2).
3.3. Time-Intensity Curves. Averaged signal intensities at
eachtimepointforMS-325aregiveninTable1.Thecontrast
between enhanced area and myocardium increased to 1.56±
0.06 (1.35–1.77) at t1,1 .62±0.04 (1.4–1.76) at t2,a n d1 .61±
0.06 (1.3–1.8) at t3. The contrast between enhanced area
a n db l o o dp o o ld e c r e a s e dt o−0.7 ± 0.11 (−0.97–0.03) at t1,
−0.54 ± 0.1( −0.92–0) at t2,a n d−0.38 ± 0.1( 0 .72–0) at t3
(Figure 3).
4. Discussion
Our study shows considerable diﬀerences between LGE
performed with a standard extracellular contrast agent (Gd-
DTPA) versus a novel intravascular contrast agent (MS-
325, gadofosveset). The accuracy of LGE with MS-325 as
comparedtoLGEwithGd-DTPAwashighest54 ±4min ut es4 The Scientiﬁc World Journal
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Figure 2: This ﬁgure shows the mean transmurality detected with
MS-325 as a percentage of the transmurality previously detected
with the extracellular CA (LGE). The columns show the results
grouped for diﬀerent degrees of transmurality with extracellular
CA. Transmurality at t1 was underestimated with MS-325 indepen-
dent of transmurality, while transmurality of 25–50% at t2 (107%)
and transmurality of 25–50% and 50–75% at t3 were overestimated
(129% and 103%, resp.) using MS-325.
after contrast injection resulting in a sensitivity of 84% with
a speciﬁcity of 98%. Transmurality of LGE was signiﬁcantly
underestimated with the intravascular agent.
4.1.LateGadoliniumEnhancement. Thepresentstudy shows
that MS-325 enhances myocardial scar somewhat similarly
to extracellular contrast agent. However, the segmental anal-
ysis showed considerable disagreement between intra- and
extravascular contrast media. With some exceptions for sub-
endocardial infarcts (<50% transmural enhancement), there
was signiﬁcant underestimation of the number of infarct
segments and the transmurality of the segments compared
to extracellular CA.
Signal intensities of the blood pool remained nearly con-
stant with a small initial increase after 26 minutes followed
byaslightdecreaseafter54minutes,whileSIoftheenhanced
area continuously increased (Table 1). These data agree with
thecharacteristicsofMS-325publishedbyParmeleeetal.[1]
and the results from other albumin-bound intravascular CA
[11] and can be explained by two principal mechanisms:
the high level of plasma albumin binding leads to vascular
retention and consistent signal from blood pool. On the
other hand, MS-325 binds reversibly to albumin and 5–15%
is unbound. This portion of CA behaves similarly to extra-
cellular CA and diﬀuses into the extracellular compartment,
leading to increasing contrast between normal myocardium
and progressively enhancing scar tissue.
The relationship among infarct age, size, CA dosage, dis-
tribution, and timing has been established for extracellular
CA [23–25], but for intravascular CA, little information has
been provided as yet. Recently, Saeed et al. [26]p e r f o r m e d
LGE imaging in 8 pigs at 10, 20, and 40 after administra-
tion of 0.026mmol/kg P792 (Vistarem), an intravascular,
gadolinium-based CA with a plasma half-life ranging from
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myocardium extracellular CA
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Figure 3: Contrast between enhanced area and normal
myocardium increased from t1 to t3 as enhanced segments showed
increasing signal intensities and normal myocardium is assumed to
be eﬀectively nulliﬁed using the correct inversion prepulse (look
locker approach). As blood pool consistently showed the highest
signal intensity over the time, blood pool-enhanced area contrast
decreased from t1 to t2 and t3 due to increasing SI in the enhanced
area and nearly constant SI of the blood pool. The dotted line (∗)
shows data for the extracellular CA Gd-DTPA extracted from a
previous study [22]. Using Gd-DTPA (0.2mmol/kg bodyweight),
the contrast between enhanced area and normal myocardium
increased continuously 4 minutes (t1)a n d2 6m i n u t e s( t2)a f t e rC A
administration. Contrast between enhanced area and blood pool
decreased from t1 to t2 (prepulse delay 275ms, TE 3.6ms, TR 8ms,
ﬂip angle 15◦).
22 minutes in mice to 29 minutes in rats and 41 minutes
in rabbits [27]. The chemical structure of P792 with a
Gd-based compound (DOTA) provided with hydrophilic
arms combines a high relaxivity with vascular retention and
restriction from fast diﬀusion out of normal microvessels.
Our data are comparable to those found in previous
studiesusingotherintravascularCAthatshowedgoodagree-
ment between extracellular CA, intravascular CA, and his-
tomorphology [10]. Flacke et al. report good delineation of
nonreperfused myocardial infarction with a long imaging
window due to long blood pool persistence but relatively low
CNRandslightoverestimationcomparedtoextracellularCA
in a rat model 1 week after infarction [10].
The transmural extent and signal behavior using MS-325
may be inﬂuenced by the following factors.
In contrary to P792, vascular retention of MS-325 is
relatedtothebindingtoplasmaalbumin,anddiﬀusionofthe
unbound component to the extracellular compartment can
be observed where MS-325 behaves similarly to extracellular
CA. In contrary to Flacke et al. [24], our data rather sug-
gest an underestimation of the transmurality of infarcted
segments, particularly early after CA injection. This may be
attributed to the fact that the mean infarct age in our study
group was 36 months. The histological correlative for the
detectedenhancementmaythusconsiderablyvarycomparedThe Scientiﬁc World Journal 5
to that of Flacke et al. [24]. However, Flacke et al. are the
ﬁrst authors to describe the detection of myocardial delayed
enhancement using MS-325, compared to a conventional
extravascular gadolinium-based CA. To which extent the
infarct age and subsequent histomorphological changes inﬂ-
uence the dimensions of LGE using MS-325 cannot be deri-
ved from our data.
The unbound portion of MS-325 diﬀuses into the extra-
cellular compartment of myocardial scar where its relaxivity
is supposed to decrease due to the missing interaction with
albumin [28]. However, Caravan et al. showed that in
vitro unbound MS-325 has still a higher relaxivity of 6.6
mmol−1sec−1 compared to Gd-DTPA (3.5mmol−1sec−1)
[19]. Additionally, at the clinical dose of 0.05mmol/kg used
in this study, saturation of albumin may already occur and
will lead to a larger distribution volume including the scar
tissue [29]. Consequently, the exact amount of MS-325 pass-
ing the capillary membrane, the washout kinetics, and its
signal behavior are not known.
5. Limitations
In this study protocol, parallel imaging (Sense technique)
was used as it allows higher spatial resolutions and shorter
scan times, suitable for dynamic contrast-enhanced per-
fusion imaging. Thus, the computation of signal-to-noise
ratios, expedient for tracing of the signal in blood pool, scar,
and myocardium after CA administration, was not applica-
ble, as SNR may vary within the ﬁeld of view and between
repeat measurements at diﬀerent time points. Nonetheless,
the tracing of contrast as performed in this study gives
an approximate estimation of MS-325 inﬂuence on signal
intensities.
This small study with a limited sample size is a single-
centerspin-oﬀofaclinicalphaseIImulticentertrialforMRI-
based feasibility and sequence optimization of myocardial
perfusion and coronary angiography study. The clinical app-
lication could be in a protocol designed for imaging of coro-
nary arteries or veins using MS-325.
6. Conclusions
Myocardial scar can be detected with the intravascular con-
trast agent MS-325. All patients with scar revealed by Gd-
DTPA contrast-enhanced MR imaging showed myocardial
LGE with MS-325. However, both the number of segments
and the transmurality of scar were underestimated with the
intravascular contrast agent in comparison to the extracellu-
lar CA.
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